ArticleCancers2022

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.

Alberto Juan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.